Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-02-01 Sale |
2021-02-03 8:13 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $25.95 | $859,438 | 686,619 (Indirect Direct) |
View |
| 2020-12-30 Sale |
2021-01-04 8:01 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $27.82 | $921,212 | 719,738 (Indirect Direct) |
View |
| 2020-11-30 Sale |
2020-12-02 8:55 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $23.85 | $789,888 | 752,857 (Indirect Direct) |
View |
| 2020-10-29 Sale |
2020-10-30 8:24 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $26.15 | $865,949 | 785,976 (Indirect Direct) |
View |
| 2020-09-28 Sale |
2020-09-30 9:21 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $26.18 | $867,055 | 819,095 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-02-15 Tax Withholding |
2021-02-19 8:10 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Joshi Abhay COO, President, R&D |
4,848 | $28.97 | 129,722 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 9:16 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,445 | $0 | 720,064 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 9:16 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Joshi Abhay COO, President, R&D |
63,545 | $0 | 175,495 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 9:16 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
63,545 | $0 | 108,844 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 9:15 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
63,545 | $0 | 112,344 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 9:12 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary |
54,348 | $0 | 87,362 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 9:10 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
114,380 | $0 | 954,857 (Direct) |
View |
| 2020-12-31 Other |
2021-01-04 8:02 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
493 | $21.36 | 49,292 (Direct) |
View |
| 2020-12-31 Other |
2021-01-04 7:59 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
348 | $21.36 | 45,647 (Direct) |
View |
| 2020-12-15 Tax Withholding |
2020-12-22 8:39 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
1,556 | $26.75 | 48,306 (Direct) |
View |
| 2020-12-15 Tax Withholding |
2020-12-22 8:37 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
562 | $26.75 | 44,951 (Direct) |
View |
| 2020-10-13 Tax Withholding |
2020-10-15 6:57 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
66,106 | $27.62 | 840,477 (Direct) |
View |
| 2020-07-23 Option Award |
2020-10-15 6:57 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
315,352 | $0 | 840,477 (Direct) |
View |
| 2020-09-30 Tax Withholding |
2020-10-02 8:34 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
6,051 | $25.14 | 45,513 (Direct) |
View |
| 2020-09-30 Option Award |
2020-10-02 8:34 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
17,500 | $0 | 45,513 (Direct) |
View |
| 2020-09-30 Tax Withholding |
2020-10-02 8:33 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
143,269 | $25.14 | 591,231 (Direct) |
View |
| 2020-09-30 Option Award |
2020-10-02 8:33 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Foley Mark J CEO & President |
301,000 | $0 | 591,231 (Direct) |
View |
| 2020-09-30 Tax Withholding |
2020-10-02 8:32 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
5,446 | $25.14 | 49,862 (Direct) |
View |
| 2020-09-30 Option Award |
2020-10-02 8:32 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
15,750 | $0 | 49,862 (Direct) |
View |
| 2020-09-30 Tax Withholding |
2020-10-02 8:31 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Joshi Abhay COO, President, R&D |
7,382 | $25.14 | 111,950 (Direct) |
View |
| 2020-09-30 Option Award |
2020-10-02 8:31 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Joshi Abhay COO, President, R&D |
17,500 | $0 | 111,950 (Direct) |
View |
| 2020-09-30 Tax Withholding |
2020-10-02 8:30 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary |
4,236 | $25.14 | 33,014 (Direct) |
View |
| 2020-09-30 Option Award |
2020-10-02 8:30 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary |
12,250 | $0 | 33,014 (Direct) |
View |
| 2020-07-23 Option Award(A) |
2020-09-30 9:19 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
667,292 | $0 | 677,912 (Direct) |
View |
| 2020-07-23 Option Award |
2020-07-27 7:57 pm |
N/A 2029-05-13 |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
53,695 | $2.54 | 982,440 (Direct) |
View |
| 2020-07-23 Option Award |
2020-07-27 7:57 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
667,292 | $0 | 982,440 (Direct) |
View |
Ownership |
2020-07-27 7:55 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
0 | $0 | 272,073 (Direct) |
View |
| 2020-06-30 Other |
2020-07-02 8:20 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Sjuts Dustin S Chief Commercial Officer |
1,000 | $13.8 | 35,064 (Direct) |
View |
| 2020-06-30 Other |
2020-07-02 8:18 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO |
763 | $13.8 | 40,321 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:45 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | Beraud Jill Director |
18,000 | $0 | 27,000 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:42 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | Vickers Philip J. Director |
18,000 | $0 | 31,650 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:41 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | Nolet Chris Director |
18,000 | $0 | 27,000 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:39 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | GARDNER PHYLLIS Director |
18,000 | $0 | 28,500 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:35 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | BYRNES ROBERT F Director |
18,000 | $0 | 42,165 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:34 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | Russell Angus C. Director |
18,000 | $0 | 28,500 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-15 6:33 pm |
N/A 2030-05-13 |
Revance Therapeutics Inc. | RVNC | Gangolli Julian S Director |
18,000 | $0 | 28,500 (Direct) |
View |